Phase 2 study of MGTA-145 + plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.
Authors: Surbhi Sidana, Andriyana Bankova, Hitomi Hosoya, Lori S. Muffly, Shaji Kumar, Laura J. Johnston, Robert Lowsky, Everett Meyer, Andrew Rezvani, Wen-Kai Weng, Sally Arai, Matthew Joshua Frank, Parveen Shiraz, Haley Howell, Kevin A Goncalves, Veit Schmelmer, John Davis, Judith Shizuru, David Bernard Miklos
Journal: Journal of Clinical Oncology (2021)

8023 Background: MGTA-145 (GroβT), a CXCR2 agonist, has shown promising activity for HSC mobilization with plerixafor in pre-clinical models and healthy volunteers. Methods: This phase 2 single center study evaluates HSC mobilization with MGTA-145 + plerixafor and same day apheresis in patients with multiple myeloma. Patients received plerixafor 0.24 mg/kg (0.16 mg/kg if renal dysfunction) SQ, followed 2 hours later by MGTA-145 (0.03 mg/kg) IV over 3-10 minutes and apheresis within 30 minutes. Mobilization was repeated for a second day if day 1 yield was &lt; 6 x 10 6 CD34+ cells/kg. This interim analysis reports on mobilization in 10 patients (of 25 planned), including safety cohort of first 6 patients completing transplant. Primary endpoint is collection of 2 x 10 6 CD34+ cells/kg. Results: Median age was 63 years (range: 46-68), 50% were female, 22% had ISS stage 3 &amp; 50% had high-risk FISH. Induction therapy was VRD in 7 and daratumumab + VRD in 3 patients; median induction duration: 4 months (3-6) &amp; median lenalidomide exposure: 6 cycles (4-6), with &gt; VGPR in 70%. Median total stem cell yield (CD34+ cells/kg x 10 6 ) was 7.1 (3-16.2), day 1 yield was 5.4 (1.1-16.2) &amp; yield per apheresis session was 4 (1.1-16.2). 100% of patients met the primary endpoint of collecting sufficient HSCs in &lt; 2 days of mobilization + apheresis to proceed to transplant (2 x 10 6 CD34+ cells/kg). Secondary endpoints of 4 and 6 x 10 6 CD34+ cells/kg in &lt; 2 days were met in 90% &amp; 80% patients. 30% patients underwent 1 apheresis, while 70% underwent 2 sessions. MGTA-145 was well tolerated. At least 1 adverse event (AE) was seen in 90% of patients, 20% had grade 2 AEs (anemia, hypokalemia) and 20% had grade 3 AEs (worsening of baseline grade 3 anemia; hypocalcemia); all resolved. Acute &amp; transient bone pain was seen in 40% of patients (back-2, hip-1, sternum-1), all grade 1, all on day 1, &amp; resolved without intervention after 6 minutes (3-10). All 6 patients in the safety cohort have completed transplant with melphalan 200 mg/m 2 . Median of 4.1 (3.4-5.6) x 10 6 CD34+ cells/kg were infused. All patients have engrafted timely (DiPersio Blood 2009); median time to neutrophil engraftment: 12 days (11-13) &amp; platelet engraftment: 17 days (16-19). Apheresis graft analysis is available in these 6 patients. Grafts with MGTA-145+plerixafor showed high enrichment for CD90+CD45RA- among CD34+ cells, a CD34 subset of long term engrafting HSCs (median: 31% of CD34+ cells, 27-52), higher than seen with G-CSF (6%, Goncalves TCT 2021). 67% of grafts were minimal residual disease negative with next generation flow cytometry. Conclusions: This is the first study to evaluate the novel regimen of MGTA-145 + plerixafor for same day stem cell mobilization &amp; collection in myeloma/hematologic malignancies, with 100% efficacy in interim analysis and the first to demonstrate successful engraftment in patients with cells collected with this GCSF free regimen. Clinical trial information: NCT04552743.